We value your privacy
We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.
Clinical Trials
47
43 active
Approvals
104
Total approvals
Agencies
4
Regulatory bodies
Founded
N/A
Active, not recruiting
43
91.5%
Completed
2
4.3%
Unknown
NMPA
National Medical Products Administration
20
EMC
Electronic Medicines Compendium
44
SFDA
Saudi Food and Drug Authority
NPRA
National Pharmaceutical Regulatory Agency
- The Health Resources and Services Administration has approved eight pharmaceutical companies to participate in the 340B Rebate Model Pilot Program, which will begin on January 1, 2025. - Nine drugs from major manufacturers including Bristol Myers Squibb's Eliquis, Novo Nordisk's Novolog, and Janssen's Stelara will be included in the voluntary rebate program. - The pilot program allows drugmakers to provide 340B discounted pricing through a rebate model rather than upfront discounts, with HRSA planning to evaluate the program for at least one year. - The initiative follows legal challenges from Johnson & Johnson, Bristol Myers Squibb, and Eli Lilly regarding HRSA's authority to review and approve rebate models in the 340B program.
